References

Alekshun TJ, Lundbye J, Sokol L, Dailey ME. Use of bivalirudin to treat heparin-induced thrombocytopenia in a patient with idiopathic giant cell myocarditis. Conn Med 70: 69-71, 2006.

Allie DE, Lirtzman MD, Wyatt CH, Keller VA, Khan MH, Khan MA, Fail PS, Hebert CJ, Ellis SD, Mitran E, Chaisson G, Stagg S Jr, Allie AA, Walker CM. Bivalirudin as a foundation anticoagulant in peripheral vascular disease: a safe and feasible alternative for renal and iliac interventions. J Invasive Cardiol 15:334-342, 2003.

Allie DE, Hall P, Shammas NW, Safian R, Laird JR, Young JJ, Virmani A. The Angiomax Peripheral Procedure Registry of Vascular Events Trial (APPROVE): in hospital and 30 day results. J Invasive Cardiol 16:651-656, 2004.

Almond CSD, Harrington J, Thiagarajan R, Duncan CN, LaPierre R, Halwick D, Blume ED, del Nido PJ, Neufeld EJ, McGown FX. Successful use of bivalirudin for cardiac transplantation in a child with heparin-induced thrombocytopenia. J Heart Lung Transplant 25:1376-1379, 2006.

Alving BM. How I treat heparin-induced thrombocytopenia and thrombosis. Blood 101: 31-37, 2003.

Antman EM, Braunwald E. A second look at bivalirudin. Am Heart J 142:929-931, 2001.

Antman EM, McCabe CH, Braunwald E. Bivalirudin as a replacement for unfractio-nated heparin in unstable angina/non ST-elevation myocardial infarction: observations from the TIMI 8 trial. Am Heart J 143:229-234, 2002.

Baker T, Chan R, Hill F. Anticoagulant monitoring techniques in a heparin-induced thrombocytopenia patient undergoing cardiopulmonary bypass using bivalirudin anticoagulant. J Extra Corpor Technol 36:371-374, 2004.

Bates SM, Weitz JI. Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin. Am J Cardiol 82:12P-18P, 1998.

Bates SM, Weitz JI. The mechanism of action of thrombin inhibitors. J Invasive Cardiol 12(suppl F):27F-32F, 2000.

Berilgen JE, Nguyen PH, Baker KR, Rice L. Bivalirudin treatment of heparin-induced thrombocytopenia [abstr]. Blood 102:537a, 2003.

Berkowitz SD. Bivalirudin in heparin-induced thrombocytopenia (HIT) or heparin induced thrombocytopenia and thrombosis syndrome (HITTS) patients [abstr]. Blood 94(suppl 1): 101b, 1999a.

Berkowitz SD. Antigenic potential of bivalirudin [abstr]. Blood 94 (suppl 1):102b, 1999b.

Bichler J, Siebeck M, Maschler R, Pelzer H, Fritz H. Determination of thrombin-hirudin complex in plasma with an enzyme-linked immunoabsorbent assay. Blood Coagul Fibrinolysis 2:129-133, 1991.

Bittl JA. Comparative safety profiles of hirulog and heparin in patients undergoing coronary angioplasty. The Hirulog Angioplasty Study Investigators. Am Heart J 130:658-665,1995.

Bittl JA, Strony J, Brinker JA, Ahmed WH, Meckel CR, Chaitman BR, Maraganore J, Deutsch E, Adelman B. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. N Engl J Med 333:764-769, 1995.

Bittl JA, Chaitman BR, Feit F, Kimball W, Topol EJ. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J 142:952-959, 2001.

Bott JN, Reddy K, Krick S. Bivalirudin use in off-pump myocardial infarction revascu-larization in patients with heparin-induced thrombocytopenia. Ann Thorac Surg 76:273-275, 2003.

Bufton MG, Rubin WD, Springhorn ME, Miller CL, Senuty EJ, Gannon MK. Bivalirudin effect on the INR and experience with prolonged inpatient and outpatient anticoagulation with bivalirudin for treatment of leg ischemia and arterial thrombosis due to HIT-TS [abstr]. Blood 100:124b, 2002a.

Bufton MG, Rubin WD, Penz JF. The effect of bivalirudin on the INR and pro-thrombin time when used as a peri-operative anticoagulant in an obese patient with pannicu-litis and a history of HIT-TS [abstr]. Blood 100:124b, 2002b.

Campbell KR, Mahaffey KW, Lewis BE, Weitz JI, Berkowitz SD, Ohman EM, Califf RM. Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention. J Invasive Cardiol 12(suppl F):14F-19F, 2000a.

Campbell KR, Wildermann N, Janning C, Lewis B, Kelton J, Green D, Kottke-Marchant K, Berkowitz SD, Mahaffey KW. Bivalirudin during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia: interim results of the ATBAT Trial [abstr]. Am J Cardiol 86(suppl 1):73i-74i, 2000b.

Cannon CP, Maraganore JM, Loscalzo J, McAllister A, Eddings K, George D, Selwyn AP, Adelman B, Fox I, Braunwald E, Ganz P. Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease. Am J Cardiol 71:778-782, 1993.

Carswell CI, Plosker GL. Bivalirudin: a review of its potential place in the management of acute coronary syndromes. Drugs 62:841-870, 2002.

Chamberlin JR, Lewis B, Leya F, Wallis D, Messmore H, Hoppensteadt D, Walenga JM, Moran S, Fareed J, McKiernan T. Successful treatment of heparin-associated throm-bocytopenia and thrombosis using Hirulog. Can J Cardiol 11:511-514, 1994.

Chew DP, Bhatt DL, Lincoff AM, Moliterno DJ, Brener SJ, Wolski KE, Topol EJ. Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. Circulation 103:961-966, 2001.

Cho L, Chew DP, Moliterno DJ, Roffi M, Ellis SG, Franco I, Bajzer C, Bhatt DL, Dorosti K, Simpfendorder C, Yadaz JS, Brener S, Raymond R, Whitlow P, Topol EJ, Lincoff AM. Safe and efficacious use of bivalirudin for percutaneous coronary intervention with adjunctive platelet glycoprotein IIb/IIIa receptor inhibition. Am J Cardiol 91:742-743, 2003.

Chong BH. Heparin-induced thrombocytopenia. J Thromb Haemost 1:1471-1478, 2003.

Cicala C, Bucci MR, Maraganore JM, Cirino G. Hirulog effect in rat endotoxin shock. Life Sci 57:307-313, 1995.

Clayton SB, Acsell JR, Crumbley AJ, Schakelford AG, Uber WE. Cardiopulmonary bypass with bivalirudin in type II heparin-induced thrombocytopenia. Ann Thorac Surg 78:2167-2169, 2004.

Cohen DJ, Lincoff AM, Lavelle TA, Chen HL, Bakhai A, Berezin RH, Jackman D, Sarembock IJ, Topol EJ. Economic evaluation of bivalirudin with provisional glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for percutaneous coronary intervention: Results from the REPLACE-2 Trial. J Am Coll Cardiol 44: 1792-1800, 2004.

Compton A. A practical cost analysis of bivalirudin. Pharmacotherapy 22:119S-127S, 2002.

Dager WE, White RH. Treatment of heparin-induced thrombocytopenia. Ann Pharmac-other 36:489-503, 2002.

Dang CH, Durkalski VL, Nappi JM. Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia. Pharmacotherapy 26:461-468, 2006.

Davis Z, Anderson R, Short D, Garber D, Valgiusti A. Favorable outcome with bivalirudin anticoagulation during cardiopulmonary bypass. Ann Thorac Surg 75:264-265, 2003.

de Denus S, Spinier SA. Clinical monitoring of direct thrombin inhibitors using the ecarin clotting time. Pharmacotherapy 22:433-435, 2002.

Despotis GJ, Hogue CW, Saleem R, Bigham M, Skubas N, Apostolidou I, Qayam A, Joist JH. The relationship between hirudin and activated clotting time: implications for patients with heparin-induced thrombocytopenia undergoing cardiac surgery. Anesth Analg 93:28-32, 2001.

Dyke CM, Koster A, Veale JJ, Maier GW, McNiff T, Levy JH Preemptive use of bivalirudin for urgent on-pump coronary artery bypass grafting in patients with potential heparin-induced thrombocytopenia. Ann Thorac Surg 80:299-303, 2005.

Dyke CM, Smedira NG, Koster A, Aronson S, McCarthy HL, Kirshner R, Lincoff AM, Spiess BD. A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass. The EVOLU-TION-ON study. J Thorac Cardiovasc Surg 131:533-539, 2006.

Dyke CM, Aldea G, Koster A, Smedira N, Avery E, Aronson S, Spiess BD, Lincoff AM. Off-pump coronary artery bypass with bivalirudin for patients with heparin-induced thrombocytopenia or anti-platelet factor 4/heparin antibodies. Ann Thorac Surg 2007; in press.

Direct Thrombin Inhibitor Trialists' Collaborative Group. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data. Lancet 359:294-302, 2002.

Eichler P, Lubenow N, Strobel U, Greinacher A. Antibodies against lepirudin are polyspecific and recognize epitopes on bivalirudin. Blood 103:613-616, 2004.

Fareed J, Lewis BE, Callas DD, Hoppensteadt DA, Walenga JM, Bick RL. Anti-thrombin agents: the new class of anticoagulant and antithrombotic drugs. Clin Appl Thromb Hemost 5(suppl 1):S45-S55, 1999.

Fenton JW II, Ofosu FA, Brezniak DV, Hassouna HI. Thrombin and antithrombotics. Semin Thromb Hemost 24:87-91,1998.

Finks S. Bivalirudin use in carotid endarterectomy in a patient with heparin-induced thrombocytopenia. Ann Pharmacother 40:340-343, 2006.

Fox I, Dawson A, Loynds P, Eisner J, Findlen K, Levin E, Hanson D, Mant T, Wagner J, Maraganore J. Anticoagulant activity of HirulogTM, a direct thrombin inhibitor, in humans. Thromb Haemost 69:157-163, 1993.

Francis RB Jr, Kawanishi D, Baruch T, Mahrer P, Rahimtoola S, Feinstein DL. Impaired fibrinolysis in coronary artery disease. Am Heart J 115:776-780,1988.

Francis JL, Drexler A, Gwyn G. Successful use of bivalirudin in the treatment of patients suspected, or at risk of, heparin-induced thrombocytopenia [abstr]. Blood 104(suppl): 105b, 2004.

Fuchs J, Cannon CP. Hirulog in the treatment of unstable angina. Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial. Circulation 92:727-733, 1995.

Ginsberg JS, Nurmohamed MT, Gent M, MacKinnon B, Stevens P, Weitz J, Maraganore J, Hirsh J. Effects on thrombin generation of single injections of Hirulog in patients with calf vein thrombosis. Thromb Haemost 72:523-525, 1994a.

Ginsberg JS, Nurmohamed MT, Gent M, MacKinnon B, Sicurella J, Brill-Edwards P, Levine MN, Panju AA, Powers P, Stevens P, Turpie AGG, Weitz J, Buller HR, ten Cate JW, Neemeh J, Adelman B, Fox I, Maraganore J, Hirsh J. Use of Hirulog in the prevention of venous thrombosis after major hip or knee surgery. Circulation 90:2385-2389, 1994b.

Gladwell TD. Bivalirudin: a direct thrombin inhibitor. Clin Ther 24:38-58, 2002.

Gosselin RC, Dager WE, King JH, Janatpour K, Mahackian K, Larkin EC, Owings JT. Effect of direct thrombin inhibitors, bivalirudin, lepirudin and argatroban, on prothrombin time and INR values. Am J Clin Pathol 121:593-599, 2004.

Gordon G, Rastegar H, Schumann R, Deiss-Shrem J, Denman W. Successful use of bivalirudin for cardiopulmonary bypass in a patient with heparin-induced thrombo-cytopenia. J Cardiothorac Vasc Anesthesiol 17:632-635, 2003.

Griessbach U, Sturzebecher J, Markwardt F. Assay of hirudin in plasma using a chromogenic thrombin substrate. Thromb Res 37:347-350,1985.

Hamelink JK, Tang DB, Barr CF, Jackson MR, Reid TJ, Gomez ER, Alving BM. Inhibition of platelet deposition by combined hirulog and aspirin in a rat carotid endarterectomy model. J Vasc Surg 21:492-498, 1995.

Hamsten A, Wiman B, de Faire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 313:1557-1563, 1985.

Hartman CA, Faria CE, Mago K. Visual compatibility of bivalirudin with selected drugs. Am J Health Syst Pharm 61:1774, 1776, 2004.

Irvin W, Sica D, Gehr T, McAllister A, Rogge M, Charenkavanich S, Adelman B. Pharmacodynamics (PD) and kinetics (PK) of bivalirudin (BIV) in renal failure (RF) and hemodialysis (HD) [abstr]. Clin Pharmacol Ther 65:202, 1999.

Itoh H, Cicala C, Douglas GJ, Page CP. Platelet accumulation induced by bacterial endotoxin in rats. Thromb Res 83:405-419, 1996.

Jabr K, Johnson JH, McDonald MH, Walsh DL, Martin WD, Johnson AC, Pickett JM. Plasma-modified ACT can be used to monitor bivalirudin (Angiomax®) anticoagulation for on-pump cardiopulmonary bypass surgery in a patient with heparin-induced thrombocytopenia. J Extra Corpor Technol 36:174-177, 2004.

Jackson MR, Reid TJ, Tang DB, O'Donnell SD, Gomez ER, Alving BM. Anti-thrombotic effects of hirulog in a rat carotid endarterectomy model. J Surg Res 60:15-22, 1996.

Kaplan KL, Francis CW. Direct thrombin inhibitors. Semin Hematol 39:187-196, 2002.

Katzen BT, Ardid MI, MacLean AA, Kovacs MF, Zemel G, Benenati JF, Powell A, Samuels S. Bivalirudin as an anticoagulation agent: safety and efficacy in peripheral interventions. J Vasc Interv Radiol 16:1183-1187, 2005.

Keating FK, Dauerman HL, Whitaker DA, Sobel BE, Schneider DJ. The effects of bivalirudin compared with those of unfractionated heparin plus eptifibatide on inflammation and thrombin generation and activity during coronary intervention. Coron Artery Dis 16:401-405, 2005a.

Keating FK, Dauerman HL, Whitaker DA, Sobel BE, Schneider DJ. Increased expression of platelet P-selectin and formation of platelet-leukocyte aggregates in blood from patients treated with unfractionated heparin plus eptifibatide compared with biva-lirudin. Thromb Res 118:361-369, 2005b.

Kelly AB, Maraganore JM, Bourdon P, Hanson SR, Harker LA. Antithrombotic effects of synthetic peptides targeting various functional domains of thrombin. Proc Natl Acad Sci USA 89:6040-6044, 1992.

Kiser TH, Fish DN. Evaluation of bivalirudin treatment for heparin-induced thrombo-cytopenia in critically ill patients with hepatic and/or renal dysfunction. Pharma-cotherapy 26:452-460, 2006.

Koster A, Hansen R, Grauhan O, Hausmann H, Bauer M, Hetzer R, Kuppe H, Mertzlufft F. Hirudin monitoring using TAS ecarin clotting time in patients with heparin-induced thrombocytopenia type II. J Cardiothorac Vasc Anesth 14:249-252, 2000.

Koster A, Chew D, Grundel M, Bauer M, Kuppe H, Spiess BD. Bivalirudin monitored with the ecarin clotting time for anticoagulation during cardiopulmonary bypass. Anesth Analg 96:383-386, 2003a.

Koster A, Chew D, Grundel M, Hausmann H, Grauhan O, Kuppe H, Spiess BD. An assessment of different filter systems for extracorporeal elimination of bivalirudin: an in vitro study. Anesth Analg 96:1316-1319, 2003b.

Koster A, Dyke CM, Aldea G, Smedira NG, McCarthy HL II, Aronson S, Hetzer R, Avery E, Spiess BD, Lincoff AM. Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial. Ann Thorac Surg 83:572-577, 2007.

Kranzhofer R, Maraganore JM, Baciu R, Libby P. Systemic thrombin inhibition by Hirulog does not alter medial smooth muscle cell proliferation and inflammatory activation after vascular injury in the rabbit. Cardiovasc Drugs Ther 13:429-434, 1999.

Lauer MA. Cost analysis of bivalirudin in percutaneous coronary intervention. J Invasive Cardiol 12(suppl F):37F-40F, 2000.

Lee A, Freeman J, Green SJ, Ong LY, Marchant D. Routine use of bivalirudin is safe and efficacious in carotid artery stenting [abstr]. Catheter Cardiovasc Interv 65:112, 2005.

Leger AJ, Jacques SL, Badar J, Kaneider NC, Derian CK, Andrade-Gordon P, Covic L, Kuliopulos A. Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis. Circulation 113:1244-1254, 2006.

Lidon RM, Theroux P, Juneau M, Adelman B, Maraganore J. Initial experience with a direct antithrombin, Hirulog, in unstable angina. Anticoagulant, antithrombotic, and clinical effects. Circulation 88:1495-1501,1993.

Lidon RM, Theroux P, Lesperance J, Adelman B, Bonan R, Duval D, Levesque J. A pilot, early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction. Circulation 89: 1567-1572,1994.

Lin PH, Bush RL, Peden EK, Zhou W, Guerrero M, Henao EA, Kougias P, Mohiuddin I, Lumsden AB. Carotid artery stenting with neuroprotection: assessing the learning curve and treatment outcome. Am J Surg 190:850-857, 2005.

Lincoff AM, Bittl JA, Kleiman NS, Kereiakes DJ, Harrington RA, Sarembook IJ, Jack-man JD, Mehta S, Maierson EF, Chew DP, Topol EJ. The REPLACE 1 Trial: a pilot study of bivalirudin versus heparin during percutaneous coronary intervention with stenting and GP IIb/IIIa blockade [abstr]. J Am Coll Cardiol 39(suppl A):16A, 2002a.

Lincoff AM, Kleiman NS, Kottke-Marchant K, Maierson ES, Maresh K, Wolski KE, Topol EJ. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). Am Heart J 143:847-853, 2002b.

Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Kereiakes DJ, Rutsch W, Wilcox RG, deFeyter PJ, Vahanian A, Topol EJ. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein Ilb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 289:853-863, 2003.

Mahaffey KW. Anticoagulation for acute coronary syndromes and percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Curr Cardiol Rep 3:362-370, 2001.

Mahaffey KW, Lewis BE, Wildermann NM, Berkowitz SD, Oliverio RM, Turco MA, Shalev Y, Lee PV, Traverse JH, Rodriguez AR, Ohman EM, Harrington RA, Califf RM, ATBAT Investigators. The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results. J Invasive Cardiol 15: 611-616, 2003.

Mann MJ, Tseng E, Ratcliffe M, Strattman G, De Silva A, DeMarco T, Achorn N, Moskalik W, Hoopes C. Use of bivalirudin, a direct thrombin inhibitor, and its reversal with modified ultrafiltration during heart transplantation in a patient with heparin-induced thrombocytopenia. J Heart Lung Transplant 24:222-225, 2005.

Maraganore JM, Adelman BA. Hirulog: a direct thrombin inhibitor for management of acute coronary syndromes. Coron Artery Dis 7:438-448, 1996.

Maraganore JM, Bourdon P, Jablonski J, Ramachandran KL, Fenton JW II. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry 29:7095-7101, 1990.

Maraganore T, Oshima FA, Sugitachi A. Comparison of anticoagulant and anti-thrombotic activities of hirulog-1 and argatroban (MD-805) [abstr]. Thromb Haemost 65:651, 1991.

Merry AF, Raudkivi P, Middleton NG, McDougall JM, Nand P, Mills BP, Webber BJ, Frampton CM. Bivalirudin versus heparin and protamine in off pump coronary artery bypass surgery. Ann Thorac Surg 77:925-931, 2004.

Nawarskas JJ, Anderson JR. Bivalirudin: a new approach to anticoagulation. Heart 3: 131-137, 2001.

Parry MA, Maraganore JM, Stone SR. Kinetic mechanism for the interaction of Hirulog with thrombin. Biochemistry 33:14807-14814,1994.

Pinto DS, Stone GW, McLaurin BT, Cox DA, Shi C, Schneider EA, Machon DA, Berezin RH, Mehran R, Moses JW, Ohman EM, White DW, Bertran ME, Lincoff AM, Cohen DJ. Cost-effectiveness of bivalirudin monotherapy for patients undergoing an early invasive management for acute coronary syndromes without ST-Elevation: results from the randomized ACUITY Trial [abstr]. Am J Cardiol 98:195M, 2006.

Pötzsch B, Hund S, Madlener K, Unkrig C, Müller-Berhaus G. Monitoring of recombinant hirudin: assessment of a plasma-based ecarin clotting time assay. Thromb Res 86:373-383, 1997.

Ramirez LM, Carman TL, Begelman SM, AlMahameed A, Joseph D, Kashyap V, White DA, Andersen-Harris K, Bartholomew JR. Bivalirudin in patients with clinically suspected HIT or history of HIT [abstr]. Blood 106:269a, 2005.

Reed MD, Bell D. Clinical pharmacology of bivalirudin. Pharmacotherapy 22:105S-111S, 2002.

Reid TJ III, Alving BM. A quantitative thrombin time for determining levels of hirudin and Hirulog. Thromb Haemost 70:608-616, 1993.

Ren S, Fenton JWII, Maraganore JM, Angel A, Shen GX. Inhibition by Hirulog-1 of generation of plasminogen activator inhibitor-1 from vascular smooth-muscle cells induced by thrombin. J Cardiovasc Pharmacol 29:337-342, 1997.

Robison JG, Crawford F Jr, Uber W. Use of bivalirudin for suspected heparin-induced thrombocytopenia during lower extremity revascularization. Vasc Dis Manag 3: 359-363, 2006.

Robson R. The use of bivalirudin in patients with renal impairment. J Invasive Cardiol 12(suppl F):33F-36F, 2000.

Robson R, White H, Aylward P, Frampton C. Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender. Clin Pharmacol Ther 71:433-439, 2002.

Sakata K, Kurata C, Taguchi T, Suzuki S, Kobayashi A, Yamazaki N, Rydzewski A, Takada Y, Takada A. Clinical significance of plasminogen activator inhibitor in patients with exercise-induced ischemia. Am Heart J 120:831-838, 1990.

Sarembock IJ, Gertz SD, Thome LM, McCoy KW, Ragosta M, Powers ER, Maraganore JM, Gimple LW. Effectiveness of hirulog in reducing restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. J Vasc Res 33:308-314, 1996.

Scatena R. Bivalirudin: a new generation antithrombotic drug. Exp Opin Invest Drugs 9:1119-1127, 2000.

Schneider DJ, Keating F, Sobel BE. Greater inhibitory effects of bivalirudin compared with unfractionated heparin plus eptifibatide on thrombin-induced platelet activation. Coron Artery Dis 17:471-476, 2006.

Sciulli TM, Mauro VF. Pharmacology and clinical use of bivalirudin. Ann Pharmac-other 36:1028-1041, 2002.

Sharma GVRK, Lapsley D, Vita JA, Sharma S, Coccio E, Adelman B, Loscalzo J. Usefulness and tolerability of hirulog, a direct thrombin-inhibitor, in unstable angina pectoris. Am J Cardiol 72:1357-1360, 1993.

Shammas N, Lemke JH, Dippel EJ, McKinney DE, Takes VS, Youngblut M, Harris M. Bivalirudin in peripheral vascular interventions: a single center experience. J Invasive Cardiol 15:401-404, 2003.

Shen GX, Ren S, Fenton JW II. Transcellular signaling and pharmacological modulation of thrombin-induced production of plasminogen activator inhibitor-1 in vascular smooth muscle cells. Semin Thromb Hemost 24:151-156,1998.

Smedira NG, Dyke CM, Koster A, Jurmann M, Bhatia DS, Hu T, McCarthy HL, Lincoff AM, Spiess BD, Aronson S. Anticoagulation with bivalirudin for off-pump coronary artery bypass grafting: The results of EVOLUTION-OFF study. J Thorac Cardiovasc 131:686-692, 2006.

Spannagl M, Bichler J, Birg A, Lill H, Schramm W. Development of a chromogenic substrate assay for the determination of hirudin in plasma. Blood Coagul Fibrino-lysis 2:121-127,1991.

Spiess BD, DeAnda A, McCarthy A, Yeatman D, Harness. HL, Katlaps G. Off pump CABG in a patient with HITT anticoagulated with bivalirudin: a case report [abstr]. Anesth Analg 93:SCA70, 2002.

Spinler SA. New concepts in heparin-induced thrombocytopenia: Diagnosis and management. J Thromb Thrombolysis 21:17-21, 2006.

Stone GW, Bertrand M, Colombo A, Dangas G, Farkouh ME, Feit F, Lansky AJ, Lincoff AM, Mehran R, Moses JW, Ohman M, White HD. Acute catheterization and urgent intervention triage strategy (ACUITY) trial: Study design and rationale. Am Heart J 148:764-775, 2004.

Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, White HD, Pocock SJ, Ware JH, Feit F, Colombo A, Aylward PE, Cequier AR, Darius H, Desmet W, Ebrahimi R, Hamon M, Rasmussen LH, Rupprecht HJ, Hoeskstra J, Mehran R, Ohman EM. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 355:2203-2216, 2006.

The Medicines Company. Angiomax (bivalirudin) package insert. Cambridge, MA, 2005.

Theroux P, Perez-Villa F, Waters D, Lesperance J, Shabani F, Bonan R. Randomized double-blind comparison of two doses of Hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction. Circulation 91:2132-2139, 1995.

Thiagarajan P, Wu KK. Mechanisms of antithrombotic drugs. Adv Pharmacol 46: 297-324, 1999.

Topol EJ, Bonan R, Jewitt D, Sigwart U, Kakkar W, Rothman M, de Bono D, Ferguson J, Willerson JT, Strony J, Ganz P, Cohen MD, Raymond R, Fox I, Maraganore J, Adelman B. Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation 87:1622-1629,1993.

Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compounding 6:311-315, 2002.

Vasquez JC, Vichiendilokkul A, Mahmood S, Baciewicz FA Jr. Anticoagulation with bivalirudin during cardiopulmonary bypass in cardiac surgery. Ann Thorac Surg 74:2177-2179, 2002.

Veale JJ, McCarthy HLM, Palmer G, Dyke CM. Use of bivalirudin as an anticoagulant during cardiopulmonary bypass. J Am Soc Extra-Corporeal Technol 37:296-302, 2005.

Walenga JM, Hoppensteadt D, Koza M, Pifarre R, Fareed J. Comparative studies on various assays for the laboratory evaluation of r-hirudin. Semin Thromb Hemost 17:103-112, 1991.

Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 121:535-555, 2003.

Warkentin TE. Anticoagulation for cardiopulmonary bypass: Is a replacement for heparin on the horizon? J Thorac Cardiovasc Surg 131:515-516, 2006.

Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia and cardiac surgery. Ann Thorac Surg 76:2121-2131, 2003.

Warkentin TE, Koster A. Bivalirudin: a review. Expert Opin Pharmacother 6: 1349-1371, 2005.

Warkentin TE, Greinacher A, Craven S, Dewar L, Sheppard JI, Ofosu FA. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation. Thromb Haemost 94:958-964, 2005.

Wasowicz M, Vegas A, Borger MA, Harwood S. Bivalirudin anticoagulation for cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia. Can J Anesth 52:1093-1098, 2005.

Weitz JI, Hirsh J. New antithrombotic agents. Chest 114(suppl):715S-727S, 1998.

Weitz J, Maraganore JM. The thrombin-specific anticoagulant, bivalirudin, completely inhibits thrombin-mediated platelet aggregation [abstr]. Am J Cardiol 88(suppl 5A):83G, 2001.

White HD. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet 358:1855-1863, 2001.

White HD, Chew DP. Bivalirudin: an anticoagulant for acute coronary syndromes and coronary interventions. Expert Opin Pharmacother 3:777-788, 2002.

White HD, Aylward PE, Frey MJ, Adgey AAJ, Nair R, Hillis WS, Shalev Y, Brown MA, French JK, Collins R, Maraganore J, Adelman B. Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Circulation 96:2155-2161, 1997.

Wiggins BS, Spinier S, Wittkowsky AK, Stringer KA. Bivalirudin: a direct thrombin inhibitor for percutaneous transluminal coronary angioplasty. Pharmacotherapy 22:1007-1018, 2002.

Wittkowsky AK. The role of thrombin inhibition during percutaneous coronary intervention. Pharmacotherapy 22:97S-104S, 2002.

Xue M, Fenton JW II, Shen GX. Hirulog-1 reduces expression of platelet-derived growth factor in neointima of rat carotid artery induced by balloon catheter injury. J Vasc Res 37:82-92, 2000.

Xue M, Ren S, Welch S, Shen GX. Hirulog-like peptide reduces balloon catheter injury induced neointima formation in rat carotid artery without increase in bleeding tendency. J Vasc Res 38:144-152, 2001.

Your Heart and Nutrition

Your Heart and Nutrition

Prevention is better than a cure. Learn how to cherish your heart by taking the necessary means to keep it pumping healthily and steadily through your life.

Get My Free Ebook


Post a comment